[{"id":"589fc224-1f44-451f-847a-4d0ffa6361d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02257424","created_at":"2021-01-18T10:36:10.936Z","updated_at":"2024-07-02T16:36:18.245Z","phase":"Phase 1/2","brief_title":"Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma","source_id_and_acronym":"NCT02257424","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" IL2","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600R • BRAF V600D • BRAF V600E + BRAF V600K","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600R • BRAF V600D • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2022-01-20"}]